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Summary
Background Prediction of response to anthracycline-based therapy for breast cancer is challenging. We aimed to assess 
the value of HER2 and TOP2A as predictive markers of response to anthracycline-based adjuvant therapy in patients 
with early breast cancer.
Methods We did a meta-analysis of individual patient data from ﬁ ve randomised adjuvant trials that compared 
anthracycline-based regimens with cyclophosphamide, methotrexate, and ﬂ uorouracil (CMF) regimens. We assessed 
the status of HER2 and TOP2A genes with ﬂ uorescent in-situ hybridisation. Tumour samples were submitted to an 
external laboratory for validation. We calculated hazard ratios (HR) to compare event-free survival (EFS) and overall 
survival in patients receiving anthracycline-based treatment with those receiving CMF in two HER2 cohorts (HER2 
ampliﬁ ed and non-ampliﬁ ed tumours) and in three TOP2A cohorts (normal, ampliﬁ ed, and deleted tumours).
Findings We analysed data for 3452 patients for HER2 and 3102 patients for TOP2A. For EFS, HRs were 0·89 (95% CI 
0·79–1·01) for HER2 non-ampliﬁ ed patients and 0·71 (0·58–0·86) for HER2-ampliﬁ ed patients (pinteraction=0·0485); for 
overall survival, HRs were 0·91 (95% CI 0·79–1·05) for HER2 non-ampliﬁ ed patients and 0·73 (0·59–0·89) for 
HER2-ampliﬁ ed patients (pinteraction=0·0718). In analysis of TOP2A status, HRs for EFS were 0·88 (0·78–1·00) for 
normal, 0·63 (0·46–0·87) for deleted, and 0·62 (0·43–0·90) for ampliﬁ ed (pinteraction=0·0513); HRs for overall survival 
were 0·89 (0·78–1·03) for normal, 0·68 (0·49–0·95) for deleted, and 0·67 (0·46–0·98) for ampliﬁ ed (pinteraction=0·1608). 
When patients with TOP2A-deleted and TOP2A-ampliﬁ ed tumours were grouped together (altered cohort) and 
compared with data from patients with normal TOP2A tumours, HRs for EFS were 0·64 (0·50–0·81) for altered and 
0·88 (0·78–1·00) for normal (pinteraction=0·0183); HRs for overall survival were 0·67 (0·52–0·86) for altered and 0·89 
(0·78–1·03) for normal (pinteraction=0·0455).
Interpretation Although HER2 ampliﬁ cation and combined TOP2A ampliﬁ cation and deletion may have some value 
in the prediction of responsiveness to anthracycline-based chemotherapy, our ﬁ ndings do not support the use of 
anthracyclines only in patients with HER2-ampliﬁ ed or TOP2A-aberrated tumours.
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Introduction
Findings from several retrospective analyses of 
randomised trials have suggested that anthracycline-
containing adjuvant therapy might be beneﬁ cial to only 
those patients with breast cancer who have HER2 gene 
ampliﬁ cation or protein overexpression,1–4 but this eﬀ ect 
cannot be explained by any biological rationale. One of 
the intracellular targets of anthracycline is the 
topoisomerase IIα protein—the gene for which, TOP2A, 
is on chromosome 17q12-q21.5 Other retrospective 
analyses have suggested that anthracycline-containing 
adjuvant therapy might be most eﬀ ective in patients 
whose tumours carry ampliﬁ ed TOP2A.6–8 However, this 
association was not seen in a study reported in 2008.9 
Two studies suggested that TOP2A gene deletion might 
also confer increased sensitivity to anthracyclines,10,11 
although, as with HER2, this eﬀ ect cannot be explained 
by any biological rationale.5
These studies have lent support to the idea of a tailored 
approach to the use of anthracyclines. Nevertheless, none 
of them alone could safely lead to ﬁ rm conclusions for 
daily practice, because small study sample sizes have 
necessitated caution in application to routine care of 
patients. Thus, in this meta-analysis we aimed to 
corroborate or reject individual study ﬁ ndings. We 
analysed data from ﬁ ve adjuvant trials in which patients 
were randomly allocated to treatment with cyclo-
phosphamide, methotrexate, and ﬂ uorouracil (CMF) or 
anthracycline-based therapy. In December, 2008, we 
presented preliminary results with data from 1944 patients.12 
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Here we report the ﬁ nal results with data from 3452 patients 
to assess the predictive value of HER2 and 3102 patients to 
assess the predictive value of TOP2A.
Methods
Trial eligibility
Phase 3 trials were eligible for inclusion in our meta-
analysis if they were a randomised comparison in the 
adjuvant setting between anthracycline-based therapy and 
CMF, if we had access to data from individual patients, 
and if we had access to archival primary tumour samples. 
Five trials met these criteria; detailed results of each have 
been reported previously.13–16 The webappendix (p 1) shows 
details of treatment groups for each trial. One study14 had 
three study groups, comparing CMF with two 
anthracycline-based treatments. For the purpose of this 
meta-analysis the two anthracycline-based groups were 
pooled. Data from individual patients from every trial 
were centralised at an independent statistical oﬃ  ce 
(International Drug Development Institute, Louvain-la-
Neuve, Belgium). The original ﬁ les were converted into a 
SAS database (SAS version 9.1). 
National laboratories quality control
An external laboratory (Laboratory of Cancer Biology, 
University of Tampere, Tampere, Finland) was originally 
going to do the central assessment of HER2 and TOP2A 
for all tumour specimens with sections cut from tissue 
microarrays. However, in December, 2006, the protocol 
was amended because preliminary data showed 
suboptimum concordance between results from the 
external laboratory and those from the four national 
laboratories that did the assessments for the original 
studies when the external laboratory tested HER2 and 
TOP2A on tissue microarray sections. Better concordance 
rates between the external and the national laboratories 
were reported when the external laboratory tested HER2 
and TOP2A on whole tumour sections. Therefore, the 
external laboratory retested HER2 and TOP2A on whole 
tumour sections from a randomly selected sample of 
cases from each trial. Testing for both markers at the four 
national laboratories was done by ﬂ uorescent in-situ 
hybridisation (FISH), as described in the individual 
publications.4,6,9–11 In the external laboratory, testing was 
done by FISH with three probes for HER2, TOP2A, and 
the centromere of chromosome 17 (Abbott Laboratories, 
Abbott Park, IL, USA). 
Investigators at both the external and national 
laboratories were masked to clinical outcome of each 
individual patient and to the result of that sample from 
the other laboratory. For this analysis, a tumour was 
deﬁ ned as HER2 ampliﬁ ed or TOP2A ampliﬁ ed if the 
ratio between HER2 or TOP2A gene copy number and 
number of copies of chromosome 17 centromere was two 
or more; we regarded TOP2A gene to be deleted if the 
ratio was 0·8 or lower and to be TOP2A normal if the 
ratio was greater than 0·8 but lower than two. We 
estimated concordance in HER2 and TOP2A scores 
between the external and the four national laboratories by 
calculating the proportion of cases with the same 
deﬁ nition of gene status (ie, ampliﬁ ed or non-ampliﬁ ed for 
HER2, and ampliﬁ ed, deleted, or normal for TOP2A). 
During on-site monitoring visits, local data, sample ﬂ ow, 
and FISH protocols were collected and veriﬁ ed for at least 
50 randomly selected patients in each national laboratory. 
Level of compliance to randomised interventions was 
veriﬁ ed for each individual trial.
Subgroup analysis
We prospectively deﬁ ned four biologically homogeneous 
cohorts: (1) highly hormone-sensitive tumours, deﬁ ned as 
oestrogen-receptor and progesterone-receptor positive 
(≥10% of immunostained cells), HER2 non-ampliﬁ ed, and 
grade 1–2; (2) moderately hormone-sensitive tumours, 
deﬁ ned as oestrogen-receptor positive and progesterone-
receptor negative independent of grade and HER2 gene 
status, or oestrogen-receptor and progesterone-receptor 
positive and grade 3, or HER2 gene ampliﬁ ed; (3) HER2-
ampliﬁ ed tumours which were oestrogen-receptor and 
progesterone-receptor negative; and (4) triple-negative 
tumours, deﬁ ned as oestrogen-receptor and progesterone-
receptor negative and HER2 non-ampliﬁ ed. We identiﬁ ed 
these four cohorts on the basis of gene expression 
signature studies reported in the past decade.17 Oestrogen-
receptor, progesterone-receptor, and histological grading 
were assessed at either local pathology units (Piccart and 
colleagues,14 Ejlersten and colleagues,15 and Poole and 
colleagues [NEAT and BR9601 trials]16) or the national 
laboratory (Levine and colleagues13). In Poole and 
colleagues’ trials,16 no progesterone-receptor testing was 
done. Accordingly, all cases from the NEAT and BR9601 
trials16 deﬁ ned as oestrogen-receptor positive were 
assumed to be also progesterone-receptor positive. 
Considering this assump tion, we ran the analysis by 
molecular subgroups twice—ie, with and without the data 
from the NEAT and BR9601 trials.16 The two analyses gave 
very similar results, so the molecular subgroup analyses 
include data from the NEAT and BR9601 trials.16 
Statistical analysis
The primary study endpoint was the comparison in 
terms of EFS and overall survival between patients who 
received anthracycline-based treatment and those who 
received CMF in the two HER2 cohorts (HER2 ampliﬁ ed 
and non-ampliﬁ ed tumours) and in the three TOP2A 
cohorts (TOP2A normal, ampliﬁ ed, and deleted 
tumours). We used a statistical signiﬁ cance level of 0·05, 
but individual p values should be interpreted cautiously 
in view of the many comparisons done. All additional 
analyses presented here were prospectively deﬁ ned in 
the statistical analysis plan and should be regarded as 
exploratory analyses. EFS was deﬁ ned as time from date 
of randomisation to date of ﬁ rst relapse, secondary 
tumour, or date of death without relapse (whichever 
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occurred ﬁ rst). Overall survival was deﬁ ned as time from 
date of randomisation to date of death from any cause. 
Patients who were alive (for overall survival) and disease-
free (for EFS) at the time of the analysis were censored at 
their date of last contact. We used the log-rank test to 
compare treatment groups. In a secondary EFS and 
overall survival analysis, the log-rank test was adjusted 
by the main prognostic factors—pathological tumour 
size (≤2 cm or >2 cm) and number of ipsilateral positive 
axillary nodes (node-negative, 1–3 positive nodes, or 
≥4 positive nodes). The predictive value of HER2 and 
TOP2A for the eﬀ ect of anthracyclines on EFS and 
overall survival was assessed through interaction tests. 
The χ² test for interaction had two degrees of freedom 
when patients were divided by TOP2A status into three 
cohorts (ie, normal, ampliﬁ ed, or deleted) and one 
degree of freedom when patients were allocated in two 
cohorts (ie, normal or aberrated). We used forest plots to 
show EFS and overall survival data by treatment and by 
HER2 or TOP2A status. We used Kaplan-Meier estimates 
to produce EFS and overall survival curves by treatment 
group and by HER2 or TOP2A gene status. We used SAS 
version 9.1 and SPLUS version 7 for statistical analyses.
Role of funding sources
The sponsors of the study had no role in study design, 
data collection, data analysis, data interpretation, or 
writing of the report. The corresponding author had full 
access to all the data in the study and had ﬁ nal 
responsibility for the decision to submit for publication.
Results
1003 (22%) of 4558 of patients could not be assessed in 
the meta-analysis because of an absence of data for HER2 
or TOP2A gene status (table 1). When EFS curves from 
patients who participated in the meta-analysis were 
compared with those from patients who did not, within 
each trial and by treatment group, we recorded no 
statistically signiﬁ cant diﬀ erences (data not shown). 
Table 2 shows HER2 and TOP2A gene status by trial 
and rates of concordance for HER2 and TOP2A status 
between each of the four national and the external 
laboratories. In Piccart and colleagues’ trial,14 TOP2A 
gene status was assessed only within the HER2 ampliﬁ ed 
cohort, which might explain why the rate of TOP2A 
gene ampliﬁ cation is more than double than that in the 
other trials. Likewise, the high proportion of HER2 gene 
ampliﬁ cation reported in the Ejlertsen and colleagues’ 
trial15 might be explained by most patients having 
oestrogen-receptor-negative disease. The quality control 
study showed a high concordance between the four 
national laboratories and the external laboratory in their 
deﬁ nition of HER2 gene status; concordance in TOP2A 
deﬁ nition was lower than it was for HER2 (table 2).
 Country Number 
of 
patients
Median 
age 
(years)
Node-
positive 
(n [%])
Oestrogen-
receptor-positive 
(n [%]) 
Receiving  
hormone 
therapy (n [%])
Receiving 
radiotherapy 
(n [%])
Median follow-
up ( years 
[95% CI]) 
Patients 
assessed for 
HER2  (n [%])
Patients 
assessed for 
TOP2A (n [%])
Piccart et al14 Belgium 804 49 804 (100%) 539 (67%) 346 (43%) 651 (81%) 12 (11·7–12·4) 353 (44%) 89 (11%)†
Levine et al13 Canada 716 44·5 716 (100%) 487 (68%) 0 712 (99%) 9·9 (9·8–10·0) 626 (87%) 437 (61%)
Ejlertsen et al15 Danish 980 47 627 (64%) 206 (21%) NA* 392 (40%) 11·4 (10·9–11·6) 670 (68%) 773 (79%)
Poole et al (NEAT)16 UK 1684 48 1162 (69%) 1010 (60%) NA NA 7·5 (7·4–7·6) 1508 (89%) 1508 (89%)
Poole et al (BR9601)16 UK 374 51·1 325 (87%) 236 (63%) 269 (72%) 318 (85%) 6·9 (6·7–7·0) 295 (79%) 295 (79%)
TOP2A=topoisomerase IIα. NA=not available. *Use of hormone therapy not recommended. †TOP2A assessed in  HER2 ampliﬁ ed cases only.
Table 1: Main characteristics in the ﬁ ve trials
Patients assessed HER2 status TOP2A status Concordance with external 
laboratory (number assessed in 
external laboratory / number of 
concordant cases [% concordance])
HER2(n) TOP2A 
(n)
Ampliﬁ ed 
(n [%])
Non-ampliﬁ ed 
(n [%])
Ampliﬁ ed 
(n [%])
Normal 
(n [%])
Deleted 
(n [%])
HER2 TOP2A 
Piccart et al14 353 89 74 (21%) 279 (79%) 23 (26%) 58 (65%) 8 (9%) 61/56 (92%) 50/29 (58%)
Levine et al13 626 437 152 (24%) 474 (76%) 54 (12%) 356 (82%) 27 (6%) 17/15 (88%) 14/10 (71%)
Ejlertsen et al15 670 773 245 (36%) 425 (64%) 92 (12%) 594 (77%) 87 (11%) 28/28 (100%) 28/20 (71%)
Poole et al (NEAT)16 1508 1508 310 (20%) 1198 (80%) 90 (6%) 1274 (84%) 144 (10%) 31*/30 (97%) 31*/26 (84%)
Poole et al (BR9601)16 295 295 62 (21%) 233 (79%) 16 (5%) 229 (78%) 50 (17%) 31*/30 (97%) 31*/26 (84%)
Total 3452 3102 843 (24%) 2609 (76%) 275 (9%) 2511 (81%) 316 (10%) 137/129 (94%) 123/85 (69%)
TOP2A=topoisomerase IIα. *The same national laboratory assessed NEAT and BR9601 cases.
Table 2: HER2 and TOP2A gene status by trial and rate of concordance with the external laboratory
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HER2 non-ampliﬁed
Piccart et al14
Levine et al13
Ejlertsen et al15
Poole et al (BR9601)16
Poole et al (NEAT)16
Subtotal
Test for heterogeneity χ2=9·22, p=0·0557
Test for treatment eﬀect χ2=3·22, p=0·0728
HER2 ampliﬁed
Piccart et al14
Levine et al13
Ejlertsen et al15
Poole et al (BR9601)16
Poole et al (NEAT)16
Subtotal
Test for heterogeneity χ2=0·8, p=0·9379
Test for treatment eﬀect χ2=12·38, p=0·0004
Total
Test for interaction χ2=3·89, p=0·0485
Test for treatment eﬀect χ2=11·82, p=0·0006
37/88
119/231
105/226
50/119
185/604
496/1268
17/29
59/85
79/128
18/31
65/148
238/421
734/1689
101/191
120/243
81/199
30/114
166/594
498/1341
19/45
33/67
58/117
16/31
59/162
185/422
683/1763
26/88
81/231
91/226
40/119
147/604
385/1268
13/29
50/85
79/128
16/31
61/148
219/421
604/1689
70/191
88/243
67/199
24/114
138/594
387/1341
14/45
30/67
60/117
16/31
51/162
171/422
558/1763
HER2 non-ampliﬁed
Piccart et al14
Levine et al13
Ejlertsen et al15
Poole et al (BR9601)16
Poole et al (NEAT)16
Subtotal
Test for heterogeneity χ2=7·02, p=0·1347
Test for treatment eﬀect χ2=1·61, p=0·2039
HER2 ampliﬁed
Piccart et al14
Levine et al13
Ejlertsen et al15
Poole et al (BR9601)16
Poole et al (NEAT)16
Subtotal
Test for heterogeneity χ2=0·93, p=0·9205
Test for treatment eﬀect χ2=9·64, p=0·0019
Total
Test for interaction χ2=3·24, p=0·0718
Test for treatment eﬀect  χ2=8·08, p=0·0045
TOP2A deleted
Piccart et al14
Levine et al13
Ejlertsen et al15
Poole et al (BR9601)16
Poole et al (NEAT)16
Subtotal
Test for heterogeneity χ2=3·68, p=0·4516
Test for treatment eﬀect χ2=8·07, p=0·0045
TOP2A ampliﬁed
Piccart et al14
Levine et al13
Ejlertsen et al15
Poole et al (BR9601)16
Poole et al (NEAT)16
Subtotal
Test for heterogeneity χ2=3·29, p=0·5100
Test for treatment eﬀect χ2=6·27, p=0·0123
0/4
13/15
37/50
12/23
35/75
97/167
6/8
13/22
29/46
2/10
12/39
62/125
0/4
11/15
37/50
8/23
31/75
87/167
5/8
12/22
27/46
2/10
11/39
57/125
2/4
3/12
23/37
8/27
25/69
61/149
4/15
13/32
21/46
3/6
11/51
52/150
3/4
5/12
20/37
8/27
28/69
64/149
6/15
15/32
19/46
3/6
13/51
56/150
TOP2A deleted
Piccart et al14
Levine et al13
Ejlertsen et al15
Poole et al (BR9601)16
Poole et al (NEAT)16
Subtotal
Test for heterogeneity χ2=3·36, p=0·4990
Test for treatment eﬀect χ2=5·22, p=0·0223
TOP2A ampliﬁed
Piccart et al14
Levine et al13
Ejlertsen et al15
Poole et al (BR9601)16
Poole et al (NEAT)16
Subtotal
Test for heterogeneity χ2=2·42, p=0·6588
Test for treatment eﬀect χ2=4·28, p=0·0386
TOP2A altered (ampliﬁed or deleted)
Piccart et al14
Levine et al13
Ejlertsen et al15
Poole et al (BR9601)16
Poole et al (NEAT)16
Subtotal
Test for heterogeneity χ2=1·85, p=0·7638
Test for treatment eﬀect χ2=13·81, p=0·0002
Total (normal and altered)
Test for interaction χ2=5·56, p=0·0183
Test for treatment eﬀect χ2=12·15, p=0·0005
1·31 (0·90–1·91)
0·95 (0·73–1·22)
0·83 (0·62–1·10)
0·54 (0·34–0·85)
0·88 (0·71–1·08)
0·89 (0·79–1·01)
0·72 (0·37–1·39)
0·60 (0·39–0·92)
0·73 (0·52–1·03)
0·81 (0·42–1·60)
0·73 (0·51–1·04)
0·71 (0·58–0·86)
0·83 (0·75–0·92)
CMF
(o/N)
Anthracyclines
(o/N)
Hazard ratio
(95% CI)
CMF
(o/N)
Anthracyclines
(o/N)
Hazard ratio
(95% CI)
Favours
CMF
Favours
anthracyclines
Favours
CMF
Favours
anthracyclines
1·22 (0·78–1·91)
1·05 (0·78–1·42)
0·80 (0·58–1·10)
0·55 (0·33–0·91)
0·93 (0·73–1·17)
0·91 (0·79–1·05)
0·70 (0·33–1·50)
0·71 (0·45–1·11)
0·74 (0·53–1·04)
0·98 (0·49–1·97)
0·67 (0·46–0·97)
0·73 (0·59–0·89)
0·85 (0·75–0·95)
>100 (..)
0·26 (0·09–0·76)
0·62 (0·36–1·06)
0·47 (0·19–1·16)
0·78 (0·47–1·28)
0·63 (0·46–0·87)
0·37 (0·12–1·17)
0·71 (0·34–1·50)
0·54 (0·30–0·97)
2·35 (0·39–14·07)
0·69 (0·31–1·54)
0·62 (0·43–0·90)
>100 (..)
0·22 (0·06–0·80)
0·65 (0·39–1·11)
0·76 (0·29–2·03)
0·80 (0·47–1·35)
0·68 (0·49–0·95)
0·44 (0·11–1·70)
0·66 (0·30–1·45)
0·66 (0·37–1·17)
2·46 (0·41–14·90)
0·61 (0·26–1·45)
0·67 (0·46–0·98)
0·86 (0·30–2·44)
0·50 (0·28–0·91)
0·57 (0·38–0·85)
0·73 (0·33–1·60)
0·74 (0·49–1·13)
0·64 (0·50–0·81)
0·82 (0·73–0·92)
0·79 (0·24–2·60)
0·46 (0·25–0·88)
0·65 (0·44–0·95)
1·03 (0·44–2·43)
0·73 (0·47–1·14)
0·67 (0·52–0·86)
0·83 (0·74–0·94)
6/12
26/37
66/96
14/33
47/114
159/292
676/1583
5/12
23/37
64/96
10/33
42/114
144/292
571/1583
6/19
16/44
44/83
11/33
36/120
113/299
476/1519
9/19
20/44
39/83
11/33
41/120
120/299
560/1519
TOP2A altered (ampliﬁed or deleted)
Piccart et al14
Levine et al13
Ejlertsen et al15
Poole et al (BR9601)16
Poole et al (NEAT)16
Subtotal
Test for heterogeneity χ2=2·46, p=0·6518
Test for treatment eﬀect χ2=10·21, p=0·0014
Total (normal and altered)
Test for interaction χ2=4, p=0·0455
Test for treatment eﬀect χ2=8·77, p=0·0031
0·2 1·0 10
A Event-free survival Overall survival
B Event-free survival Overall survival
0·2 1·0 10
4 4
4 4
1 1
4 4
4 4
4 4
1 1
Total (normal, deleted, and ampliﬁed)
Test for interaction χ2=5·94, p=0·0513
Test for treatment eﬀect  χ2=12·32, p=0·0004
676/1583 571/1583 476/1519560/1519 Total (normal, deleted, and ampliﬁed)
Test for interaction χ2=3·66, p=0·1608
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Figure 1: Interaction between gene status and treatment eﬀ ect, by survival analysis
Survival by (A) HER2 status and (B) TOP2A status. CMF=cyclophosphamide, methotrexate, and ﬂ uorouracil. o=observed events.
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The beneﬁ t of treatment with anthracyclines over 
treatment with CMF was greater for individuals with 
HER2 gene ampliﬁ cation than it was for individuals 
without HER2 gene ampliﬁ cation when analysing EFS 
(pinteraction=0·0485), but not when analysing overall survival 
(pinteraction=0·0718; ﬁ gure 1 and ﬁ gure 2). We recorded no 
signiﬁ cant diﬀ erence in the beneﬁ t of treatment with 
anthracyclines over treatment with CMF when assessing 
the three separate TOP2A cohorts in terms of either EFS 
(pinteraction=0·0513) or overall survival (pinteraction=0·1608; 
Number at risk
Anthracycline-based
CMF
1341
1268
1156
1044
1001
895
815
719
498
427
179
146
36
19
14
11
1
2
..
..
0
0·2
0·4
0·6
0·8
1341
1268
1258
1169
1141
1024
970
860
621
546
288
247
110
81
37
32
3
2
..
..
0 2 4 6 8 10 12 14 16 18
Year
0 2 4 6 8 10 12 14 16 18
Year
1·0
Pr
ob
ab
ili
ty
A
Number at risk
Anthracycline-based
CMF
422
421
314
284
253
210
210
168
141
95
59
31
9
10
2
5
0
1
..
..
0
0·2
0·4
0·6
0·8
422
421
375
350
301
258
242
206
166
127
82
64
32
27
6
11
0
2
..
..
1·0
Pr
ob
ab
ili
ty
Number at risk
Anthracycline-based
CMF
150
125
121
93
105
68
89
54
55
27
21
7
2
2
0
2
0
0
..
..
0
0·2
0·4
0·6
0·8
150
125
143
107
124
84
100
68
64
40
32
18
7
8
2
4
0
0
..
..
1·0
Pr
ob
ab
ili
ty
B
Number at risk
Anthracycline-based
CMF
149
167
114
106
89
83
70
63
45
31
10
9
1
1
0
1
0
0
..
..
0
0·2
0·4
0·6
0·8
149
167
130
136
105
95
79
70
53
38
19
17
7
5
3
2
0
0
..
..
1·0
Pr
ob
ab
ili
ty
Number at risk
Anthracycline-based
CMF
299
292
235
199
194
151
159
117
100
58
31
16
3
3
0
3
0
0
..
..
0
0·2
0·4
0·6
0·8
299
292
273
243
229
179
179
138
117
78
51
35
14
13
5
6
0
0
..
..
1·0
Pr
ob
ab
ili
ty
Patients Events Risk group
1341
1268
498
496
Anthracycline-based
CMF
Patients Events Risk group
422
421
185
238
Anthracycline-based
CMF
Patients Events Risk group
150
125
56
52
Anthracycline-based
CMF
Patients Events Risk group
1341
1268
387
385
Anthracycline-based
CMF
Patients Events Risk group
422
421
171
219
Anthracycline-based
CMF
Patients Events Risk group
150
125
52
57
Anthracycline-based
CMF
Event-free survival HER2 non-ampliﬁed
Event-free survival HER2 ampliﬁed
Event-free survival TOP2A ampliﬁed
Overall survival HER2 non-ampliﬁed
Overall survival HER2 ampliﬁed
Overall survival TOP2A ampliﬁed
Patients Events Risk group
149
167
64
97
Anthracycline-based
CMF
Patients Events Risk group
149
167
61
87
Anthracycline-based
CMF
Event-free survival TOP2A deleted Overall survival TOP2A deleted
Patients Events Risk group
299
292
120
159
Anthracycline-based
CMF
Patients Events Risk group
299
292
113
144
Anthracycline-based
CMF
Event-free survival TOP2A altered Overall survival TOP2A altered
Number at risk
Anthracycline-based
CMF
1220
1291
1020
1046
883
883
717
704
403
406
116
114
5
6
3
1
0
0
..
..
0
0·2
0·4
0·6
0·8
1220
1291
1124
1174
995
1016
841
848
499
518
207
227
80
83
17
29
0
1
..
..
1·0
Pr
ob
ab
ili
ty
Patients Events Risk group
1220
1291
440
517
Anthracycline-based
CMF
Patients Events Risk group
1220
1291
363
427
Anthracycline-based
CMF
Event-free survival TOP2A normal Overall survival TOP2A normal
Figure 2: Event-free survival and overall survival, by gene status 
Survival by (A) HER2 status (B) TOP2A status. CMF=cyclophosphamide, methotrexate, and ﬂ uorouracil. 
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ﬁ gure 1 and ﬁ gure 2). However, when TOP2A 
ampliﬁ cations and deletions were combined (altered 
cohort), we recorded a signiﬁ cant diﬀ erence in the beneﬁ t 
of treatment with anthracyclines over treatment with CMF 
between patients with normal TOP2A status and those 
with altered TOP2A status when analysing both EFS 
(pinteraction=0·0183) and overall survival (pinteraction=0·0455; 
ﬁ gure 1 and ﬁ gure 2). 
When adjusted according to the main prognostic factors 
(ie, pathological tumour size and number of positive 
ipsilateral axillary nodes), HRs for the eﬀ ect of 
anthracyclines versus CMF in patients with HER2 gene 
ampliﬁ cation were 0·70 (95% CI 0·57–0·85; p=0·0004) 
for EFS and 0·73 (0·59–0·90; p=0·003) for overall survival, 
and, for patients without HER2 gene ampliﬁ cation, were 
0·85 (0·75–0·96; p=0·012) for EFS and 0·87 (0·75–1·01; 
p=0·061) for overall survival. After adjustment, the beneﬁ t 
of treatment with anthracyclines over treatment with CMF 
was not statistically diﬀ erent between individuals with 
HER2 ampliﬁ cation and those without HER2 ampliﬁ -
cation in either EFS (pinteraction=0·10) or overall survival 
(pinteraction=0·17). 
For TOP2A, adjusted HRs were 0·62 (0·42–0·92; 
p=0·019) for EFS and 0·68 (0·45–1·02; p=0·060) for 
overall survival for patients with TOP2A ampliﬁ cation, 
0·57 (0·41–0·81; p=0·002) for EFS and 0·64 (0·45–0·92; 
p=0·016) for overall survival for patients with TOP2A 
deletion, and 0·86 (0·76–0·98; p=0·024) for EFS and 
0·87 (0·75– 1·00; p=0·057) for overall survival for 
patients with TOP2A normal. After adjustment, the 
beneﬁ t of treatment with anthracyclines over treatment 
with CMF diﬀ ered signiﬁ cantly between the three 
groups in terms of EFS (pinteraction=0·04) but not in overall 
survival (pinteraction=0·19). When TOP2A ampliﬁ cations 
and deletions were combined, adjusted HRs were 0·60 
(0·47–0·77; p=0·0001) for EFS and 0·63 (0·48–0·82; 
p=0·0005) for overall survival in patients with TOP2A 
alterations, and 0·86 (0·76–0·98; p=0·024) for EFS and 
0·87 (0·75–1·00; p=0·056) for overall survival in 
patients with TOP2A-normal tumours. The beneﬁ t of 
treatment with anthracyclines over treatment with CMF 
diﬀ ered signiﬁ cantly between the two groups in terms 
of both EFS (pinteraction=0·013) and overall survival 
(pinteraction=0·033).
Of 2588 patients with data that could be assessed, 
740 (29%) were deﬁ ned as highly hormone-sensitive, 
878 (34%) as moderately hormone-sensitive, 311 (12%) 
as HER2 ampliﬁ ed and oestrogen-receptor and 
progesterone-receptor negative, and 659 (25%) as triple 
negative (ﬁ gure 3 and ﬁ gure 4). We recorded no 
signiﬁ cant diﬀ erence in the treatment eﬀ ect of 
anthracyclines or CMF between molecular subgroups, 
but individuals with HER2-ampliﬁ ed tumours seemed 
to respond better to anthracyclines and those with highly 
hormone-sensitive tumours seemed to respond better 
to CMF (ﬁ gure 3). EFS HRs for HER2 ampliﬁ ed and 
HER2 non-ampliﬁ ed moderately hormone-sensitive 
tumours were 0·78 (95% CI 0·55–1·11; p=0·17) and 
0·79 (0·59–1·05; p=0·11), respectively. We compared 
treatment groups by TOP2A gene status within the 
HER2 positive molecular subgroup, and, in all three 
cohorts, anthracycline-based therapy seemed to be more 
eﬀ ective than CMF (webappendix p 2). 
Discussion
Our ﬁ ndings show a greater beneﬁ t from anthracycline-
based adjuvant therapy in patients with HER2 gene 
ampliﬁ cation than in patients without such ampliﬁ cation 
and in patients with TOP2A gene alterations than in 
patients with normal TOP2A status. However, our study 
also shows that patients with HER2 non-ampliﬁ ed or 
TOP2A normal tumours might have some additional 
beneﬁ t from treatment with anthracyclines, which 
suggests a quantitative rather than a qualitative 
interaction between anthracycline activity and HER2 or 
TOP2A status. 
In this meta-analysis we included trials with 
diﬀ erences in the type of anthracycline-based regimens 
or in the CMF schedules used (webappendix p 1), which 
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Figure 3: Interaction between molecular subgroup and treatment eﬀ ect (event-free survival analysis)
CMF=cyclophosphamide, methotrexate, and ﬂ uorouracil. o=observed events.
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is a potential limitation in the interpretation of the 
study results, although we recorded similar associations 
in the interaction between the activity of treatments 
and HER2 or TOP2A status in each individual trial. 
Two pooled analyses of previously published data have 
investigated HER2, but not TOP2A, in the same setting 
with similar results.18,19 Neither of these studies did an 
external quality control substudy for the testing of 
HER2 or TOP2A. Our external TOP2A-testing quality 
control substudy suggests that procedures for TOP2A 
testing by FISH need increased standardisation to 
achieve better reproducibility. Our study design chose 
the external laboratory as the gold standard, but because 
tumour samples assessed in the external laboratory 
were not tested in another laboratory, and because 
samples from the four national laboratories were not 
cross-compared, we cannot identify the reason behind 
the recorded discordance. 
A unique aspect of this study is the planned exploratory 
analysis in which patients were grouped into one of four 
molecularly deﬁ ned cohorts. In view of the retrospective 
nature of this assessment and the restricted sample size, 
the results of this subgroup analysis have to be regarded as 
merely hypothesis-generating and should not lead to 
changes in clinical practice. This analysis, prompted by 
the known molecular and clinical heterogeneity of breast 
cancer,17 suggests that, in contradiction to previously 
reported studies that analysed the HER2 non-ampliﬁ ed 
cohort as a homogeneous group,1–4,6,9,10,18,19 diﬀ erential 
beneﬁ t from anthracyclines might exist within the HER2 
non-ampliﬁ ed cohort. In our analysis individuals with 
triple-negative or moderately hormone-sensitive tumours 
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seemed to respond better to treatment with anthracyclines 
than to treatment with CMF. Because all triple-negative 
tumours and almost 90% of moderately hormone-sensitive 
tumours from this study did not carry TOP2A gene 
ampliﬁ cation, other mechanisms of increased sensitivity 
to anthracycline might exist. We deﬁ ned triple-negative 
tumours as such if oestrogen-receptor and progesterone-
receptor immunostaining was less than 10%, and not less 
than 1% as suggested in international guidelines.20 
However we regard this discrepancy as irrelevant with 
regard to the suggested beneﬁ t from anthracyclines in 
patients who do not carry TOP2A gene ampliﬁ cation. 
Triple-negative tumours and moderately hormone-
sensitive tumours are often characterised by high 
proliferation rates.21–23 Proliferation signals can lead to 
topoisomerase II α protein over-expression independently 
of TOP2A gene status.24,25 Indeed, data reported 
elsewhere26–27 draw attention to the absence of concordance 
between TOP2A gene status and protein concentrations 
within the same tumour. Ideally, quantiﬁ cation of nuclear 
concentrations of the topoisomerase II α protein (ie, the 
active protein isoform) might be the most appropriate way 
to investigate its predictive value.28 Other biological factors 
not related to TOP2A have been investigated as potential 
markers of sensitivity to anthracyclines. Among those, 
polysomy of chromosome 17, which could be a marker of 
genomic instability and DNA repair dysfunction, might 
play a part.29 Moreover, factors involved in the regulation of 
the stroma–tumour interaction or in the immune response 
against a tumour might also be involved.30–32 Future studies 
looking at molecular markers to predict response to 
anthracyclines will have to take into account the fact that 
probably only a multifactorial system will predict 
responsiveness to anthracyclines.
In conclusion, our ﬁ ndings do not justify routine use 
of HER2 and TOP2A as molecular markers to predict 
anthracycline activity, because women with non-HER2 
ampliﬁ ed and non-TOP2A altered tumours seem to 
derive beneﬁ ts from treatment with anthracyclines, and 
because problems exist with the reproducibility of TOP2A 
gene status assessment by FISH.
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